Galapagos (NASDAQ:GLPG) Upgraded by BidaskClub to Hold

BidaskClub upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a research note issued to investors on Tuesday, January 16th.

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research upgraded Galapagos from a sell rating to a hold rating in a research note on Wednesday, October 11th. BTIG Research restated a buy rating and set a $118.00 price objective on shares of Galapagos in a research note on Monday, November 20th. Stifel Nicolaus restated a buy rating and set a $120.00 price objective on shares of Galapagos in a research note on Sunday, October 29th. ValuEngine lowered Galapagos from a hold rating to a sell rating in a research note on Friday, December 1st. Finally, Morgan Stanley reiterated an overweight rating and issued a $123.00 target price (up previously from $92.00) on shares of Galapagos in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $111.00.

Galapagos (NASDAQ:GLPG) opened at $108.83 on Tuesday. The firm has a market capitalization of $5,543.47, a PE ratio of -118.29 and a beta of 1.85. Galapagos has a 12-month low of $67.26 and a 12-month high of $121.09.

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada raised its stake in Galapagos by 254.3% during the 2nd quarter. Royal Bank of Canada now owns 4,170 shares of the biotechnology company’s stock valued at $319,000 after acquiring an additional 2,993 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Galapagos during the 3rd quarter valued at $3,072,000. Northern Trust Corp increased its position in shares of Galapagos by 2.9% during the 2nd quarter. Northern Trust Corp now owns 18,480 shares of the biotechnology company’s stock valued at $1,414,000 after purchasing an additional 524 shares during the period. Bank of New York Mellon Corp increased its position in shares of Galapagos by 7.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 40,813 shares of the biotechnology company’s stock valued at $4,152,000 after purchasing an additional 2,720 shares during the period. Finally, Alps Advisors Inc. increased its position in shares of Galapagos by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 50,045 shares of the biotechnology company’s stock valued at $5,092,000 after purchasing an additional 4,177 shares during the period. 19.71% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2018/02/11/galapagos-glpg-lifted-to-hold-at-bidaskclub.html.

About Galapagos

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos (NASDAQ:GLPG)

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply